Browse Tag

AbbVie company

FDA fully approved Venclexta combinations for acute myeloid leukaemia

5 mins read

The FINANCIAL — Roche today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venclexta was previously granted provisional approval in this setting under the FDA’s accelerated approval programme in November 2018. Today’s FDA approval converts Venclexta’s accelerated approval in this setting to a full approval. “Today’s full approval is supported by the significant results that showed…

Read More »

FDA fully approved Venclexta combinations for acute myeloid leukaemia

5 mins read

The FINANCIAL — Roche today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive…

Allergan Aesthetics acquires Luminera dermal filler business

2 mins read

The FINANCIAL — Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into an agreement with Luminera, a privately held, aesthetics company based in Israel with a portfolio and pipeline of dermal filler products.  Under the terms of the agreement, Allergan Aesthetics will acquire Luminera’s full dermal filler portfolio and R&D pipeline further enhancing…